Pekin Hardy Strauss Inc. Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Pekin Hardy Strauss Inc. purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,050 shares of the medical equipment provider’s stock, valued at approximately $225,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in LNTH. Signaturefd LLC increased its holdings in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares during the period. Silverberg Bernstein Capital Management LLC grew its stake in Lantheus by 0.4% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after purchasing an additional 100 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the last quarter. GAMMA Investing LLC lifted its position in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 146 shares during the last quarter. Finally, Moody National Bank Trust Division increased its position in Lantheus by 1.1% during the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after buying an additional 162 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Trading Up 0.5 %

Shares of NASDAQ LNTH opened at $90.96 on Tuesday. The stock has a market cap of $6.32 billion, a price-to-earnings ratio of 15.13 and a beta of 0.51. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The company has a 50 day simple moving average of $103.13 and a two-hundred day simple moving average of $96.93.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. JMP Securities dropped their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.